Growing support for the legalization of certain psychedelic compounds, particularly for therapeutic use, has piqued interest in commercial opportunities related to the production of substances such as psilocybin, LSD, MDMA and DMT. Joshua Horn, Co-Chair of the firm’s Cannabis Law Practice, provides a concise overview of recent changes to state laws that have loosened some restrictions on these drugs, and the implications for their potential commercialization